Skip to content

Study · Not a test of the peptide alone · 2021

5 results

A potentially effective drug for patients with recurrent glioma: sermorelin.

Chang Y, Huang R, Zhai Y, Huang L, Feng Y, Wang D, Chai R, Zhang W, Hu H

Annals of translational medicine1 Mar 2021Cited by 6 (Europe PMC)

PMID33842627 (opens in a new tab)PMCIDPMC8033379 (opens in a new tab)DOI10.21037/atm-20-6561 (opens in a new tab)PepBankPUB-33842627
Read at sourcePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study5

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone5

In this study, Sermorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Sermorelin.

  1. 01Computer modelNot a test of Sermorelin aloneIn silicoEfficacy outcome

    In a computational screen of 4,865 drugs, recurrent glioma patients were predicted to be most sensitive to sermorelin.

    In plain wordsA computer model of tumour gene data predicted that recurrent glioma would be most sensitive to sermorelin. It was not tested in a living body.

    Peptide
    Sermorelin
    Outcome
    Not applicablePredicted drug sensitivity of recurrent glioma
    Study

    humann: not reported in source

    transcriptome-based Drug Resistance Scores
    Outcome group
    Tumor growth · Cancer

    Source sentences

    Summary
    After high-throughput drug screening, we found that recurrent glioma patients were most sensitive to sermorelin.
    2 context sentences
    Summary · context
    A total of 1,018 glioma patients with transcriptome sequencing data and clinical data were included in this study.
    Summary · context
    Drug Resistant Scores (DRS) of 4,865 drugs of each patient were used for screening.

    In this study, Sermorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Sermorelin.

  2. 02Computer modelNot a test of Sermorelin aloneIn silicoEfficacy outcome

    The analysis predicted that sermorelin suited recurrent glioma patients with high grade, IDH-wildtype and 1p/19q non-codeletion status.

    In plain wordsA computer model predicted that sermorelin would suit certain recurrent glioma subtypes. It was not tested in a living body.

    Peptide
    Sermorelin
    Outcome
    Not applicablePredicted sensitivity by tumour subgroup
    Study

    humann: not reported in source

    transcriptome-based Drug Resistance Scores
    Outcome group
    Tumor growth · Cancer

    Source sentences

    Summary
    Further analysis revealed that sermorelin was suitable for recurrent patients with high grade, IDH-wildtype and 1p/19q non-codeletion status.
    2 context sentences
    Summary · context
    A total of 1,018 glioma patients with transcriptome sequencing data and clinical data were included in this study.
    Summary · context
    Drug Resistant Scores (DRS) of 4,865 drugs of each patient were used for screening.

    In this study, Sermorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Sermorelin.

  3. 03Computer modelNot a test of Sermorelin aloneIn silicoMechanism

    GO and KEGG analyses suggested that sermorelin may inhibit glioma cell proliferation by cell cycle blocking.

    In plain wordsA computer analysis suggested that sermorelin may slow tumour cell growth by blocking the cell cycle. This was not tested in cells.

    Peptide
    Sermorelin
    Outcome
    DecreasePredicted effect on tumour cell proliferation
    Study

    humann: not reported in source

    transcriptome-based Drug Resistance Scores
    Outcome group
    Tumor growth · Cancer

    Source sentences

    Summary
    GO and KEGG analyses found that sermorelin may inhibit tumor cell proliferation by cell cycle blocking.
    2 context sentences
    Summary · context
    A total of 1,018 glioma patients with transcriptome sequencing data and clinical data were included in this study.
    Summary · context
    Drug Resistant Scores (DRS) of 4,865 drugs of each patient were used for screening.

    In this study, Sermorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Sermorelin.

  4. 04Computer modelNot a test of Sermorelin aloneIn silicoMechanism

    In the computational analysis, sermorelin was related to the immune system process and negatively regulated immune checkpoints and M0 macrophages.

    In plain wordsA computer analysis linked sermorelin to immune system activity. It was not tested in a living body.

    Peptide
    Sermorelin
    Outcome
    Not applicablePredicted association with immune processes
    Study

    humann: not reported in source

    transcriptome-based Drug Resistance Scores
    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    Moreover, sermorelin was also related to the immune system process and negatively regulated immune checkpoints and M0 macrophages.
    2 context sentences
    Summary · context
    A total of 1,018 glioma patients with transcriptome sequencing data and clinical data were included in this study.
    Summary · context
    Drug Resistant Scores (DRS) of 4,865 drugs of each patient were used for screening.

    In this study, Sermorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Sermorelin.

  5. 05Computer modelNot a test of Sermorelin aloneIn silicoEfficacy outcome

    Kaplan-Meier analysis suggested that the predicted benefit from sermorelin was independent of postoperative adjuvant treatment.

    In plain wordsA computer analysis suggested the predicted benefit of sermorelin did not depend on other treatment after surgery.

    Peptide
    Sermorelin
    Outcome
    Not applicablePredicted benefit by postoperative adjuvant treatment
    Study

    humann: not reported in source

    transcriptome-based Drug Resistance Scores
    Outcome group
    Tumor growth · Cancer

    Source sentences

    Summary
    Lastly, the Kaplan-Meier method showed the patient's benefit from sermorelin was independent of postoperative adjuvant treatment.
    2 context sentences
    Summary · context
    A total of 1,018 glioma patients with transcriptome sequencing data and clinical data were included in this study.
    Summary · context
    Drug Resistant Scores (DRS) of 4,865 drugs of each patient were used for screening.

    In this study, Sermorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Sermorelin.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 10:21 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.